Voyager Therapeutics Stock Forecast, Price & News

+0.08 (+2.64 %)
(As of 09/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume271,900 shs
Average Volume476,475 shs
Market Capitalization$117.98 million
P/E Ratio6.76
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive VYGR News and Ratings via Email

Sign-up to receive the latest news and ratings for Voyager Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Voyager Therapeutics logo

About Voyager Therapeutics

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.70 out of 5 stars

Medical Sector

34th out of 1,349 stocks

Biological Products, Except Diagnostic Industry

4th out of 193 stocks

Analyst Opinion: 3.2Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 2.5 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Voyager Therapeutics (NASDAQ:VYGR) Frequently Asked Questions

Is Voyager Therapeutics a buy right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Voyager Therapeutics in the last year. There are currently 9 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Voyager Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VYGR, but not buy additional shares or sell existing shares.
View analyst ratings for Voyager Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Voyager Therapeutics?

Wall Street analysts have given Voyager Therapeutics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Voyager Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Voyager Therapeutics' next earnings date?

Voyager Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Voyager Therapeutics

How were Voyager Therapeutics' earnings last quarter?

Voyager Therapeutics, Inc. (NASDAQ:VYGR) released its earnings results on Monday, August, 9th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.73) by $0.07. The company earned $1.36 million during the quarter, compared to analyst estimates of $4.04 million. Voyager Therapeutics had a trailing twelve-month return on equity of 12.63% and a net margin of 13.55%.
View Voyager Therapeutics' earnings history

How has Voyager Therapeutics' stock been impacted by COVID-19?

Voyager Therapeutics' stock was trading at $9.43 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, VYGR shares have decreased by 67.0% and is now trading at $3.11.
View which stocks have been most impacted by COVID-19

What price target have analysts set for VYGR?

13 brokerages have issued twelve-month price objectives for Voyager Therapeutics' shares. Their forecasts range from $6.00 to $45.00. On average, they expect Voyager Therapeutics' share price to reach $13.29 in the next twelve months. This suggests a possible upside of 327.4% from the stock's current price.
View analysts' price targets for Voyager Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Voyager Therapeutics' key executives?

Voyager Therapeutics' management team includes the following people:
  • Michael J. Higgins, Chairman & Chief Executive Officer
  • Allison Dorval, CFO & Principal Accounting Officer
  • Glenn F. Pierce, Chief Scientific Officer & Director
  • Robert W. Hesslein, Senior Vice President & General Counsel
  • Allen Nunnally, Chief Business Officer

Who are some of Voyager Therapeutics' key competitors?

What other stocks do shareholders of Voyager Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Voyager Therapeutics investors own include Micron Technology (MU), REGENXBIO (RGNX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Amarin (AMRN), CRISPR Therapeutics (CRSP), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO) and Editas Medicine (EDIT).

What is Voyager Therapeutics' stock symbol?

Voyager Therapeutics trades on the NASDAQ under the ticker symbol "VYGR."

Who are Voyager Therapeutics' major shareholders?

Voyager Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (5.72%), BlackRock Inc. (2.50%), JPMorgan Chase & Co. (2.44%), Morgan Stanley (1.94%), Morgan Stanley (1.94%) and Federated Hermes Inc. (1.79%). Company insiders that own Voyager Therapeutics stock include Allison Dorval, Andre Turenne, Matthew P Ottmer, Omar Khwaja and Robert W Hesslein.
View institutional ownership trends for Voyager Therapeutics

Which major investors are selling Voyager Therapeutics stock?

VYGR stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., JPMorgan Chase & Co., State Street Corp, Vanguard Group Inc., Northern Trust Corp, AQR Capital Management LLC, Geode Capital Management LLC, and Bridgeway Capital Management LLC. Company insiders that have sold Voyager Therapeutics company stock in the last year include Allison Dorval, Andre Turenne, and Omar Khwaja.
View insider buying and selling activity for Voyager Therapeutics
or view top insider-selling stocks.

Which major investors are buying Voyager Therapeutics stock?

VYGR stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Federated Hermes Inc., Morgan Stanley, Morgan Stanley, GSA Capital Partners LLP, Goldman Sachs Group Inc., Ergoteles LLC, and Tibra Equities Europe Ltd.
View insider buying and selling activity for Voyager Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Voyager Therapeutics?

Shares of VYGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Voyager Therapeutics' stock price today?

One share of VYGR stock can currently be purchased for approximately $3.11.

How much money does Voyager Therapeutics make?

Voyager Therapeutics has a market capitalization of $117.98 million and generates $171.13 million in revenue each year. The company earns $36.74 million in net income (profit) each year or $0.98 on an earnings per share basis.

How many employees does Voyager Therapeutics have?

Voyager Therapeutics employs 177 workers across the globe.

What is Voyager Therapeutics' official website?

The official website for Voyager Therapeutics is

Where are Voyager Therapeutics' headquarters?

Voyager Therapeutics is headquartered at 75 SIDNEY STREET, CAMBRIDGE MA, 02139.

How can I contact Voyager Therapeutics?

Voyager Therapeutics' mailing address is 75 SIDNEY STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at (857) 259-5340 or via email at [email protected].

This page was last updated on 9/20/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.